Irritable Bowel Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global Irritable Bowel Syndrome (IBS) Treatment Market is experiencing significant growth, with a revenue of US$ 3.8 Bn in 2024 and a projected to propel the market to a valuation of approximately US$ 8 Bn by the end of 2031, as per the latest analysis report by Fairfield Market Research.
Understanding Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is a gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, cramps, acidity, diarrhea, and constipation. It is a chronic condition that requires long-term management.
Impact of Diet on IBS
The prevalence of IBS is significantly influenced by irregular eating patterns and the frequent consumption of fried and processed foods. Such foods, high in fat, can affect the digestive system, leading to IBS. Chemical changes during frying can make food more difficult to digest, contributing to digestive discomfort.
Causes and Microbiota
IBS often follows severe episodes of diarrhea caused by bacteria or viruses and may be linked to excess or overgrowth of bacteria in the intestines. The intestinal microbiota plays a crucial role in maintaining gut health, and differences in microorganisms have been observed in IBS patients.
Factors Driving Growth
The growth of the IBS treatment market is primarily driven by increased drug usage, including anti-diarrheal medications and alosetron. Greater awareness of IBS, rising patient numbers, and increased research and development activities leading to more effective treatment drugs are expected to fuel market growth.
Challenges in Market Growth
The social stigma associated with discussing IBS symptoms is a significant challenge. Many individuals with IBS conceal their condition due to social discomfort, leading to silent suffering. Additionally, the market's high competitiveness, driven by multiple participants, poses challenges in areas like pricing and sales.
Booming U.S. Market
The U.S. IBS treatment market is thriving due to changing lifestyles, high consumption of unhealthy foods, reduced physical activity, and the availability of therapeutic medications.
Outlook in the U.K.
The U.K. market shows potential due to increasing healthcare spending and the need for efficient resource utilization in the National Health Service (NHS).
Emerging Market in China
China is emerging as a prominent market for IBS treatment, with manufacturers expanding their global footprint and technological capabilities, making therapy products more widely accessible.
Competitive Landscape
Key players in the IBS treatment market are investing in technologically advanced products and engaging in consolidation activities, such as product launches and mergers and acquisitions. Major companies profiled in the industry include Takeda Pharmaceutical Company Limited, Pfizer, Inc., Abbott Laboratories, Novartis AG, AstraZeneca PLC, Ironwood Pharmaceuticals Inc. and Allergan Plc, Bausch Health Companies Inc., GlaxoSmithKline, Plc., Lexicon Pharmaceuticals, Inc., and Sucampo Pharmaceuticals, Inc.
Market Segmentation
By Product:
• Fiber Supplements
• Anti-Diarrheal
• Anticholinergic and Antispasmodic
• Antidepressant
• Antibiotics
• Alosetron
• Lubiprostone
• Linaclotide
• NHE3
By Indication:
• Irritable Bowel Syndrome with Constipation
• Irritable Bowel Syndrome with Diarrhoea
• Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies and Stores
• Hypermarkets and Supermarkets
By Region:
• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.
- 1. Executive Summary
- 1.1. Global Irritable Bowel Syndrome Treatment Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2023
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Global Irritable Bowel Syndrome Treatment Market Outlook, 2018 – 2031
- 3.1. Global Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 3.1.1. Key Highlights
- 3.1.1.1. Fiber Supplements
- 3.1.1.2. Anti-Diarrheal
- 3.1.1.3. Anticholinergic and Antispasmodic
- 3.1.1.4. Antidepressant
- 3.1.1.5. Antibiotics Antibiotics
- 3.1.1.6. Alosetron
- 3.1.1.7. Lubiprostone
- 3.1.1.8. Linaclotide
- 3.1.1.9. NHE3
- 3.2. Global Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 3.2.1. Key Highlights
- 3.2.1.1. Irritable Bowel Syndrome with Constipation
- 3.2.1.2. Irritable Bowel Syndrome with Diarrhoea
- 3.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
- 3.3. Global Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 3.3.1. Key Highlights
- 3.3.1.1. Hospital Pharmacies
- 3.3.1.2. Retail Pharmacies
- 3.3.1.3. Drug Stores
- 3.3.1.4. Online Pharmacies and Stores
- 3.3.1.5. Hypermarkets and Supermarkets
- 3.4. Global Irritable Bowel Syndrome Treatment Market Outlook, by Region, Value (US$ Bn), 2018 – 2031
- 3.4.1. Key Highlights
- 3.4.1.1. North America
- 3.4.1.2. Europe
- 3.4.1.3. Asia Pacific
- 3.4.1.4. Latin America
- 3.4.1.5. Middle East & Africa
- 4. North America Irritable Bowel Syndrome Treatment Market Outlook, 2018 – 2031
- 4.1. North America Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 4.1.1. Key Highlights
- 4.1.1.1. Fiber Supplements
- 4.1.1.2. Anti-Diarrheal
- 4.1.1.3. Anticholinergic and Antispasmodic
- 4.1.1.4. Antidepressant
- 4.1.1.5. Antibiotics Antibiotics
- 4.1.1.6. Alosetron
- 4.1.1.7. Lubiprostone
- 4.1.1.8. Linaclotide
- 4.1.1.9. NHE3
- 4.2. North America Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 4.2.1. Key Highlights
- 4.2.1.1. Irritable Bowel Syndrome with Constipation
- 4.2.1.2. Irritable Bowel Syndrome with Diarrhoea
- 4.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
- 4.3. North America Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.3.1. Key Highlights
- 4.3.1.1. Hospital Pharmacies
- 4.3.1.2. Retail Pharmacies
- 4.3.1.3. Drug Stores
- 4.3.1.4. Online Pharmacies and Stores
- 4.3.1.5. Hypermarkets and Supermarkets
- 4.4. North America Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 4.4.1. Key Highlights
- 4.4.1.1. U.S. Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 4.4.1.2. U.S. Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 4.4.1.3. U.S. Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.4.1.4. Canada Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 4.4.1.5. Canada Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 4.4.1.6. Canada Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Irritable Bowel Syndrome Treatment Market Outlook, 2018 – 2031
- 5.1. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 5.1.1. Key Highlights
- 5.1.1.1. Fiber Supplements
- 5.1.1.2. Anti-Diarrheal
- 5.1.1.3. Anticholinergic and Antispasmodic
- 5.1.1.4. Antidepressant
- 5.1.1.5. Antibiotics Antibiotics
- 5.1.1.6. Alosetron
- 5.1.1.7. Lubiprostone
- 5.1.1.8. Linaclotide
- 5.1.1.9. NHE3
- 5.2. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 5.2.1. Key Highlights
- 5.2.1.1. Irritable Bowel Syndrome with Constipation
- 5.2.1.2. Irritable Bowel Syndrome with Diarrhoea
- 5.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
- 5.3. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.3.1. Key Highlights
- 5.3.1.1. Hospital Pharmacies
- 5.3.1.2. Retail Pharmacies
- 5.3.1.3. Drug Stores
- 5.3.1.4. Online Pharmacies and Stores
- 5.3.1.5. Hypermarkets and Supermarkets
- 5.4. Europe Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 5.4.1. Key Highlights
- 5.4.1.1. Germany Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.2. Germany Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.4.1.3. Germany Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.4. U.K. Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.5. U.K. Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.4.1.6. U.K. Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.7. France Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.8. France Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.4.1.9. France Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.10. Italy Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.11. Italy Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.4.1.12. Italy Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.13. Turkey Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.14. Turkey Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.4.1.15. Turkey Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.16. Russia Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.17. Russia Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.4.1.18. Russia Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.1.19. Rest of Europe Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 5.4.1.20. Rest of Europe Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 5.4.1.21. Rest of Europe Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, 2018 – 2031
- 6.1. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 6.1.1. Key Highlights
- 6.1.1.1. Fiber Supplements
- 6.1.1.2. Anti-Diarrheal
- 6.1.1.3. Anticholinergic and Antispasmodic
- 6.1.1.4. Antidepressant
- 6.1.1.5. Antibiotics Antibiotics
- 6.1.1.6. Alosetron
- 6.1.1.7. Lubiprostone
- 6.1.1.8. Linaclotide
- 6.1.1.9. NHE3
- 6.2. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 6.2.1. Key Highlights
- 6.2.1.1. Irritable Bowel Syndrome with Constipation
- 6.2.1.2. Irritable Bowel Syndrome with Diarrhoea
- 6.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
- 6.3. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.3.1. Key Highlights
- 6.3.1.1. Hospital Pharmacies
- 6.3.1.2. Retail Pharmacies
- 6.3.1.3. Drug Stores
- 6.3.1.4. Online Pharmacies and Stores
- 6.3.1.5. Hypermarkets and Supermarkets
- 6.4. Asia Pacific Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 6.4.1. Key Highlights
- 6.4.1.1. China Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.2. China Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.4.1.3. China Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.1.4. Japan Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.5. Japan Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.4.1.6. Japan Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.1.7. South Korea Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.8. South Korea Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.4.1.9. South Korea Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.1.10. India Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.11. India Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.4.1.12. India Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.1.13. Southeast Asia Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.14. Southeast Asia Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.4.1.15. Southeast Asia Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.1.16. Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 6.4.1.17. Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 6.4.1.18. Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Irritable Bowel Syndrome Treatment Market Outlook, 2018 – 2031
- 7.1. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 7.1.1. Key Highlights
- 7.1.1.1. Fiber Supplements
- 7.1.1.2. Anti-Diarrheal
- 7.1.1.3. Anticholinergic and Antispasmodic
- 7.1.1.4. Antidepressant
- 7.1.1.5. Antibiotics Antibiotics
- 7.1.1.6. Alosetron
- 7.1.1.7. Lubiprostone
- 7.1.1.8. Linaclotide
- 7.1.1.9. NHE3
- 7.2. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 7.2.1. Key Highlights
- 7.2.1.1. Irritable Bowel Syndrome with Constipation
- 7.2.1.2. Irritable Bowel Syndrome with Diarrhoea
- 7.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
- 7.3. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.3.1. Key Highlights
- 7.3.1.1. Hospital Pharmacies
- 7.3.1.2. Retail Pharmacies
- 7.3.1.3. Drug Stores
- 7.3.1.4. Online Pharmacies and Stores
- 7.3.1.5. Hypermarkets and Supermarkets
- 7.4. Latin America Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 7.4.1. Key Highlights
- 7.4.1.1. Brazil Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 7.4.1.2. Brazil Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 7.4.1.3. Brazil Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.4.1.4. Mexico Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 7.4.1.5. Mexico Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 7.4.1.6. Mexico Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.4.1.7. Argentina Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 7.4.1.8. Argentina Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 7.4.1.9. Argentina Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.4.1.10. Rest of Latin America Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 7.4.1.11. Rest of Latin America Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 7.4.1.12. Rest of Latin America Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, 2018 – 2031
- 8.1. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Product, Value (US$ Bn), 2018 – 2031
- 8.1.1. Key Highlights
- 8.1.1.1. Fiber Supplements
- 8.1.1.2. Anti-Diarrheal
- 8.1.1.3. Anticholinergic and Antispasmodic
- 8.1.1.4. Antidepressant
- 8.1.1.5. Antibiotics Antibiotics
- 8.1.1.6. Alosetron
- 8.1.1.7. Lubiprostone
- 8.1.1.8. Linaclotide
- 8.1.1.9. NHE3
- 8.2. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 – 2031
- 8.2.1. Key Highlights
- 8.2.1.1. Irritable Bowel Syndrome with Constipation
- 8.2.1.2. Irritable Bowel Syndrome with Diarrhoea
- 8.2.1.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhoea
- 8.3. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.3.1. Key Highlights
- 8.3.1.1. Hospital Pharmacies
- 8.3.1.2. Retail Pharmacies
- 8.3.1.3. Drug Stores
- 8.3.1.4. Online Pharmacies and Stores
- 8.3.1.5. Hypermarkets and Supermarkets
- 8.4. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook, by Country, Value (US$ Bn), 2018 – 2031
- 8.4.1. Key Highlights
- 8.4.1.1. GCC Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 8.4.1.2. GCC Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.4.1.3. GCC Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.1.4. South Africa Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 8.4.1.5. South Africa Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.4.1.6. South Africa Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.1.7. Egypt Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 8.4.1.8. Egypt Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.4.1.9. Egypt Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.1.10. Nigeria Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 8.4.1.11. Nigeria Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.4.1.12. Nigeria Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.1.13. Rest of Middle East & Africa Irritable Bowel Syndrome Treatment Market by Product, Value (US$ Bn), 2018 – 2031
- 8.4.1.14. Rest of Middle East & Africa Irritable Bowel Syndrome Treatment Market by Indication, Value (US$ Bn), 2018 – 2031
- 8.4.1.15. Rest of Middle East & Africa Irritable Bowel Syndrome Treatment Market Distribution Channel, Value (US$ Bn), 2018 – 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. Product vs Distribution Channel Heatmap
- 9.2. Manufacturer vs Distribution Channel Heatmap
- 9.3. Company Market Share Analysis, 2023
- 9.4. Competitive Dashboard
- 9.5. Company Profiles
- 9.5.1. Takeda Pharmaceutical Company Limited
- 9.5.1.1. Company Overview
- 9.5.1.2. Product Portfolio
- 9.5.1.3. Financial Overview
- 9.5.1.4. Business Strategies and Development
- 9.5.2. Pfizer, Inc.
- 9.5.2.1. Company Overview
- 9.5.2.2. Product Portfolio
- 9.5.2.3. Financial Overview
- 9.5.2.4. Business Strategies and Development
- 9.5.3. Abbott Laboratories
- 9.5.3.1. Company Overview
- 9.5.3.2. Product Portfolio
- 9.5.3.3. Financial Overview
- 9.5.3.4. Business Strategies and Development
- 9.5.4. Novartis AG
- 9.5.4.1. Company Overview
- 9.5.4.2. Product Portfolio
- 9.5.4.3. Financial Overview
- 9.5.4.4. Business Strategies and Development
- 9.5.5. AstraZeneca PLC
- 9.5.5.1. Company Overview
- 9.5.5.2. Product Portfolio
- 9.5.5.3. Financial Overview
- 9.5.5.4. Business Strategies and Development
- 9.5.6. Ironwood Pharmaceuticals Inc. and Allergan Plc
- 9.5.6.1. Company Overview
- 9.5.6.2. Product Portfolio
- 9.5.6.3. Financial Overview
- 9.5.6.4. Business Strategies and Development
- 9.5.7. Bausch Health Companies Inc.
- 9.5.7.1. Company Overview
- 9.5.7.2. Product Portfolio
- 9.5.7.3. Financial Overview
- 9.5.7.4. Business Strategies and Development
- 9.5.8. GlaxoSmithKline Plc.
- 9.5.8.1. Company Overview
- 9.5.8.2. Product Portfolio
- 9.5.8.3. Financial Overview
- 9.5.8.4. Business Strategies and Development
- 9.5.9. Lexicon Pharmaceuticals Inc.
- 9.5.9.1. Company Overview
- 9.5.9.2. Product Portfolio
- 9.5.9.3. Financial Overview
- 9.5.9.4. Business Strategies and Development
- 9.5.10. Sucampo Pharmaceuticals Inc.
- 9.5.10.1. Company Overview
- 9.5.10.2. Product Portfolio
- 9.5.10.3. Financial Overview
- 9.5.10.4. Business Strategies and Development
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook